Exact Sciences appoints Kim Popovits to Board of Directors

EXACT SCIENCES CORP

Board expanded from 9 to 10 members; Popovits appointed Class I director, term ends at 2025 annual meeting.
Popovits previously served as President and CEO of Genomic Health until Exact Sciences' 2019 acquisition.
She brings over 40 years healthcare experience, including leadership roles at Genentech and Genomic Health.
Received initial stock award valued at $375,000 per non-employee director compensation policy.
Currently serves on boards of Kiniksa Pharmaceuticals, 10x Genomics, and Talis Biomedical.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kim Popovits

Class I member of the Board

EXACT SCIENCES CORP

Effective: 2025-01-02
Filed: January 6, 2025, 6:59 PM ET

On January 2, 2025, the Board of Directors (the “Board”) of Exact Sciences Corporation (the “Company”) expanded the size of the Board from nine to ten members and appointed Kim Popovits as a Class I member of the Board with a term ending at the Company’s 2025 annual meeting of shareholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Kim Popovits was appointed as Class I member of the Board at EXACT SCIENCES CORP.

Action: appointed
Role: Class I member of the Board

Exact text from the filing

On January 2, 2025, the Board of Directors (the “Board”) of Exact Sciences Corporation (the “Company”) expanded the size of the Board from nine to ten members and appointed Kim Popovits as a Class I member of the Board with a term ending at the Company’s 2025 annual meeting of shareholders.

View on SEC.gov

Source: SEC EDGAR

accession 0001124140-25-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.